EyePoint’s DURAVYU Fails Primary Goal in Phase 3 LUGANO Trial Despite Strong Secondary Results

EyePoint DURAVYU misses primary endpoint in LUGANO Phase 3 for wet AMD. Strong secondaries: 42% treatment burden reduction, favorable safety.